Source: MarketScreener

Acura Pharmaceuticals Inc: Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K

(marketscreener.com) AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE This AMENDMENT #1 TO AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSSORY NOTE dated November 10, 2022 between Acura Pharmaceuticals, Inc. , a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067,...https://www.marketscreener.com/quote/stock/ACURA-PHARMACEUTICALS-INC-120789192/news/Acura-Pharmaceuticals-AMENDED-CONSOLIDATED-AND-RESTATED-SECURED-PROMISSORY-NOTE-Form-8-K-45619692/?utm_medium=RSS&utm_content=20231221

Read full article »
Annual Revenue
$100K-5.0M
Employees
1-25
Robert B. Jones's photo - President & CEO of Acura Pharmaceuticals Inc

President & CEO

Robert B. Jones

CEO Approval Rating

85/100

Read more